We did a check on the awesome clinicaltrials.gov website recently to see what clinical trials were happening for SJIA. The good news is that there are 7 total: 4 that are currently recruiting for patients, and another 3 that are in the planning stages but haven’t started recruiting yet.
All of the studies are for either Actemra (Tocilizumab) or Ilaris (Canakinumab). So parents whose kids are on either of those medications should check with their doctors about whether they should apply to participate in these trials.
We’ll be keeping the clinical trials section of the website updated and tweeting/blogging about new clinical trials as they are announced or when they start recruiting patients.[easytable caption=”Clinical Trials in SJIA” colwidth=”20|500|50″] no,Trials,Drug,Status
1,An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naÃƒÆ’Ã‚Â¯ve Patients With Active SJIA With and Without Fever.,Drug: Canakinumab,Recruiting
2,Extension Study Evaluating the Safety and Efficacy of Subcutaneous RoActemra/Actemra Administration in Patients With Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis,Drug: tocilizumab,Recruiting
3,A Study of RoActemra/Actemra (Tocilizumab) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis,Drug: Tocilizumab,Recruiting
4,A Study of Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab),Drug: tocilizumab,Recruiting
5,An Open-label Multi-arm Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Drug: Canakinumab,Not Yet Recruiting
6,ÃƒÅ¸-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab,Drug: Canakinumab,Not Yet Recruiting
7,a Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis Who Participated in the Study CACZ885G2301E1,Drug: Canakinumab,Not Yet Recruiting [/easytable]